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ARE WE HELPING CANCER PATIENTS QUIT SMOKING USING 
SMOKING CESSATION PROGRAMS? A SYSTEMATIC REVIEW AND 
META-SYNTHESIS OF THE LITERATURE  
Stacey M. Yemchuk, R. Gabriel Boldt, David A. Palma, Alexander 
V. Louie 
London Regional Cancer Program, London, ON 
 
Purpose: Although cigarette smoking contributes to 
approximately one third of cancer diagnoses, the effects of 
smoking on patient outcomes after a diagnosis of cancer are less 
clear. The purpose of this study was to evaluate the impact of 
the Smoking Cessation Program at our institution over a 12-
month period, and to perform a meta-synthesis of the literature 
on the effects of smoking on cancer patient outcomes.  
Methods and Materials: The Smoking Cessation Program at our 
institution was launched in March 2014. All new cancer patients 
are screened for tobacco usage. Smokers are counselled 
regarding cessation benefits and offered referral to the program. 
A Smoking Cessation Champion contacts the patient to provide 
information and counselling. Further follow up is via an 
interactive voice response telephone system. To assess the 
success of this program, accrual data at each step of the pathway 
were collected monthly during the year 2015 and evaluated. To 
supplement our institutional data, a qualitative review of the 
literature was performed in Medline by a clinical librarian to 
assess the impact of smoking on cancer patient outcomes and to 
review the most effective smoking cessation interventions. 
Results: Data collected from the Smoking Cessation Program 
indicate that in 2015, 18% of new patients were current/recent 
tobacco users. While 93% of smokers were advised of cessation 
benefits and offered referral, only 16% accepted and only 4% of 
those enrolled in the automated follow up system. In our review 
of the literature, 160 studies were identified. After abstract 
screening and review, several detrimental effects of smoking on 
cancer patient outcomes were described, including: decreased 
overall survival, increased risk of disease 
recurrence/progression, increased side effects, reduced 
performance status, increased rate of second primary cancers, 
impaired quality of life, and reduced efficacy of treatment. 
Proposed mechanisms by which these effects occur include 
decreased immune response and fibroblast proliferation, 
genomic instability, resistance to apoptosis, increased 
angiogenesis, and tissue hypoxia. A meta-analysis of smoking 
cessation interventions reported that abstinence rates were 
highest (37% at six months) in patients using a nicotine patch for 
> 14 weeks with supplementary nicotine replacement therapy 
(NRT) agents as needed. The addition of behavioural intervention 
to pharmacological agents doubles abstinence rates. 
Conclusions: Continued cigarette smoking is detrimental to 
cancer patient outcomes. The Smoking Cessation Program at our 
institution has been less successful than those described in the 
literature. Limitations of the program include challenges in 
patient access to NRT and minimal follow up. The program is 
currently undergoing modifications, including initiation of 
education sessions to engage clinicians in promoting smoking 
cessation and prescribing NRT. 
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MEETING THE INTERNATIONAL LYMPHOMA RADIATION ONCOLOGY 
GROUP CRITERIA TO DELIVER RADIOTHERAPY FOR LYMPHOMAS - 
A QUALITY IMPROVEMENT STUDY AT THE TOM BAKER CANCER 
CENTRE  
Peter Mathen, Christine Molnar, Theresa Trotter, Doug Stewart, 
Alex Balogh 
University of Calgary, Calgary, AB 
Purpose: Recent guidelines published by the International 
Lymphoma Radiation Oncology Group (ILROG) have described 
best practices for design and delivery of radiation in Hodgkin (HL) 
and non-Hodgkin lymphoma (NHL). Involved site radiation 
treatment (ISRT) is the goal of treatment, and requires that 
treatment planning incorporate pre-treatment PET and/or CT 
findings. Ideally, imaging studies should be obtained in the 
treatment position and using planned immobilization devices. 
Methods and Materials: At our institution, PET imaging is 
obtained for almost all new HL and NHL diagnoses, with patient 
supine and arms up being the standard image acquisition 
position. To meet the new ideal criteria of imaging studies being 
obtained in the treatment position and using planned 
immobilization devices, the nuclear medicine department at 
Foothills Medical Centre (single site performing all PET scans in 
the Calgary zone) was requested to scan all new HL and NHL 
patients on a flat couch, and to acquire images with arms up (for 
optimal interpretation of body images) and arms down (for 
potential finding of head and neck involvement of HL or NHL). 
While a deep inspiration breath hold technique would be ideal 
for the body scan (as this technique has been shown to reduce 
lung toxicity when RT is used to treat the mediastinum), this is 
not feasible due to the length of time of PET image acquisition. 
Results: The new PET scan technique was applied from April 1 - 
November 30, 2015. Three hundred and seventy-three patients 
were scanned. Use of the flat RT couch was discontinued after 
one month, due to weight of the couch creating a back injury 
risk for the technologists. Of the 373 patients scanned, 55 
(14.7%) received curative intent radiation therapy, either as sole 
treatment or consolidation treatment. In 37 (9.9% of scanned 
patients), PET fusion was done to aid in target definition of ISRT. 
Conclusions: Due to resource constraints, and audit of utilization 
of PET information for RT planning, there was a mutual decision 
to resume standard PET image acquisition procedures for new HL 
and NHL patients as of December 1, 2015. While the criteria of 
obtaining PET images in the treatment position and using planned 
immobilization devices is the ideal as per the ILROG guidelines, 
the low number of patients who receive RT as part of treatment 
for HL/NHL, and the even lower number for whom PET fusion 
was done to aid in target definition of ISRT, make this approach 
impractical and costly in our institution. Work is ongoing to 
identify the 15% of patients for whom curative intent RT is 
planned as sole or combined modality therapy, after staging is 
completed, to determine how ILROG best practice guidelines for 
RT delivery could be implemented. 
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A RETROSPECTIVE STUDY COMPARING RADIOTHERAPY PLANS FOR 
NON-SMALL CELL LUNG CANCER WITH GROSS TUMOUR 
DELINEATED ON FREE BREATHING CT SCAN VERSUS 4D CT SCAN  
Kate Johnson, Naseer Ahmed, Sankar Venkataraman, Shaun 
Loewen, Ethan Lyn 
University of Manitoba, Winnipeg, MB 
 
Purpose: Modern radiotherapy with 4D CT image acquisition for 
lung cancer radiation planning is precise and captures tumour 
motion, reducing the risk of missing gross disease during 
treatment. We undertook this study to compare gross tumour 
volume (GTV), planning tumour volume (PTV) and dose volume 
histograms (DVH) for organs at risk (OAR) with traditional 3D 
conformal radiotherapy (3DCRT) and plans generated on Internal 
Target Volume (ITV) with 4DCT. 
Methods and Materials: Fifteen patients with non-small cell lung 
cancer (Stage III, IV) were enrolled in the study. 3D and 4D CT 
simulation data sets were acquired at the same setting. GTV for 
primary and/or nodal disease was contoured on free breathing 
CT scan and 3DCRT plans were obtained. ITV was contoured on 
4D for primary and nodal disease on all 10 respiratory phases and 
radiation plans were generated with same beam geometry as in 
3DCRT plans. GTV, ITV, PTV and DVH on both plans were 
analyzed and compared. Overlap between the two PTVs was 
analyzed with Dice Coefficient. 
Results: Mean GTV was 115 cm3 for 3D and 139 cm3 for 4D (p = 
0.0091). Mean PTV_3D was 505cm3 and mean PTV_4D was 463cm3 
(p = 0.33). Ninety-five percent of the prescribed dose covered 
97.8% of PTV_3D and 89.0% of PTV_4D (p = 0.0036). Mean V20 to 
the lungs was 24.6 cGy for 3D and 23.4 cGy for 4D plans (p = 
0.055). Mean V40 to the heart was similar in both plans. Mean 
max dose to the cord was 2609 cGy for 3D and 2560 cGy for 4D 
